Lv1
100 积分 2022-05-11 加入
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors
2天前
已完结
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
1个月前
已完结
Therapeutic developments in pancreatic cancer
1个月前
已完结
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers
3个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
3个月前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
4个月前
已完结
The complementarity of DDR, nucleic acids and anti-tumour immunity
5个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
6个月前
已完结
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
6个月前
已完结
Cancer incidence and mortality in China, 2022
6个月前
已完结
皖公网安备34019202002308
